Fulcrum Therapeutics
FULC
47 hedge funds and large institutions have $201M invested in Fulcrum Therapeutics in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 5 reducing their positions, and 3 closing their positions.
380% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 5
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
24% more funds holding
Funds holding: 38 → 47 (+9)
4.41% more ownership
Funds ownership: 67.63% → 72.04% (+4.4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
23% less capital invested
Capital invested by funds: $262M → $201M (-$61.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.57M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$6.54M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.48M |
| 4 |
FT
Fiduciary Trust
Boston,
Massachusetts
|
+$1.68M |
| 5 |
Millennium Management
New York
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$8.02M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.26M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$692K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$558K |
| 5 |
FAM
Fred Alger Management
New York
|
-$504K |
FULC Hedge Fund Activity: Q1 2020 in Review
47 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q1 2020, worth a combined $201M — down 23% from $262M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new FULC positions and 3 closed out — a net gain of 9 holders — while 24 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $6.57M. The largest seller was Foresite Capital Management IV, cutting an estimated $8.02M.
- 47 institutional investors held Fulcrum Therapeutics (FULC) as of Q1 2020, up from 38 in Q4 2019.
- Funds reported $201M of Fulcrum Therapeutics stock for Q1 2020, down 23% quarter-over-quarter.
- 12 funds opened new Fulcrum Therapeutics positions in Q1 2020 and 3 closed out, a net change of +9 holders.
- The largest Fulcrum Therapeutics buyer in Q1 2020 was BlackRock, an estimated $6.57M added.
- The largest Fulcrum Therapeutics seller in Q1 2020 was Foresite Capital Management IV, an estimated $8.02M sold.
Based on aggregated 13F filings for Q1 2020.